0001209191-21-056971.txt : 20210920 0001209191-21-056971.hdr.sgml : 20210920 20210920202038 ACCESSION NUMBER: 0001209191-21-056971 CONFORMED SUBMISSION TYPE: 3/A PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20210909 FILED AS OF DATE: 20210920 DATE AS OF CHANGE: 20210920 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Clem Kerry M CENTRAL INDEX KEY: 0001883938 FILING VALUES: FORM TYPE: 3/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-31938 FILM NUMBER: 211264493 MAIL ADDRESS: STREET 1: 420 SAW MILL RIVER ROAD CITY: ARDSLEY STATE: NY ZIP: 10502 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACORDA THERAPEUTICS INC CENTRAL INDEX KEY: 0001008848 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 420 SAW MILL RIVER ROAD CITY: ARDSLEY STATE: NY ZIP: 10502 BUSINESS PHONE: 914-347-4300 MAIL ADDRESS: STREET 1: 420 SAW MILL RIVER ROAD CITY: ARDSLEY STATE: NY ZIP: 10502 3/A 1 doc3a.xml FORM 3/A SUBMISSION X0206 3/A 2021-09-09 2021-09-20 0 0001008848 ACORDA THERAPEUTICS INC ACOR 0001883938 Clem Kerry M 420 SAW MILL RIVER ROAD ARDSLEY NY 10502 0 1 0 0 Chief Commercial Officer Common Stock 11594 D Employee Stock Option (right to buy) 158.10 2022-03-15 Common Stock 3000 D Employee Stock Option (right to buy) 182.76 2023-03-06 Common Stock 3543 D Employee Stock Option (right to buy) 236.28 2024-03-05 Common Stock 3543 D Employee Stock Option (right to buy) 214.44 2025-03-04 Common Stock 3188 D Employee Stock Option (right to buy) 213.18 2026-03-02 Common Stock 2159 D Employee Stock Option (right to buy) 164.85 2027-03-01 Common Stock 1250 D Employee Stock Option (right to buy) 146.10 2028-03-01 Common Stock 1967 D Employee Stock Option (right to buy) 81.06 2029-03-08 Common Stock 1834 D Employee Stock Option (right to buy) 14.46 2029-11-07 Common Stock 9168 D Employee Stock Option (right to buy) 3.1572 2030-09-01 Common Stock 2501 D Includes 550 unvested restricted stock awards and 6,675 unvested restricted stock unit awards issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. 275 of the restricted stock awards vest on December 1, 2021 and 275 vest on December 1, 2022, subject to continued service. The restricted stock units each represent a contingent right to one share of the Issuer's common stock, subject to continued service, vesting in installments of 20% and 40% on March 3, 2022 and September 3, 2022, respectively. Options issued under the Issuer's 2006 Employee Incentive Plan. The shares subject to this option vested in installments and were fully vested on January 1, 2016. Options issued under the Issuer's 2006 Employee Incentive Plan. The shares subject to this option vested in installments and were fully vested on January 1, 2017. Options issued under the Issuer's 2006 Employee Incentive Plan. The shares subject to this option vested in installments and were fully vested on January 1, 2018. Options issued under the Issuer's 2006 Employee Incentive Plan. The shares subject to this option vested in installments and were fully vested on January 1, 2019. Options issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares subject to this option vested in installments and were fully vested on January 1, 2020. Options issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares subject to this option vested in installments and were fully vested on January 1, 2021. Options issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares subject to this option vest in equal quarterly installments over four years beginning on January 1, 2019, with the first quarterly installment vesting on April 1, 2019. Options issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares subject to this option vest in equal quarterly installments over two years beginning on November 7, 2019, with the first quarterly installment vesting on February 7, 2020. Options issued under the Issuer's 2015 Omnibus Incentive Compensation Plan. The shares subject to this option vest in equal quarterly installments over four years beginning on September 1, 2020, with the first quarterly installment vesting on December 1, 2020. This amendment is refiled due to incorrect Power of Attorney on the initial Form 3 filing. /s/ Kerry M. Clem 2021-09-20 EX-24.3A_1009318 2 poa.txt POA DOCUMENT LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS Exhibit 24 - POWER OF ATTORNEY For Executing Forms 3, 4 and 5 Know all by these presents, that the undersigned hereby constitutes and appoints each of Ron Cohen and Andrew Mayer or any of them acting singly, and with full power of substitution, the undersigned's true and lawful attorney-in-fact to: 1. prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the Securities and Exchange Commission (the "SEC"), a Form ID, including any amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934 or any rule or regulation of the SEC; 2. prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the SEC, Forms 3, 4 and 5, and any amendments thereto, in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder; 3. do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5, complete and execute any amendment or amendments thereto, and file such form with the SEC and any stock exchange or similar authority; and 4. take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in his/her discretion. The undersigned hereby grants to each attorney-in- fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary and proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or his/her substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is Acorda Therapeutics, Inc. assuming, any of the undersigned's responsibilities to comply with Section 16(a) of the Securities Exchange Act of 1934. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by Acorda Therapeutics, Inc., unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 9 day of September 2021. /s/ Kerry M. Clem __________________________________ Kerry Clem Notary Signature & Seal to be Placed Here: Lim Kim A. Notary Public, State of New York No. 01L16144154 Qualified in Westchester County Commission Expires Apr. 24, 2022